   |
|
|
|
|
| Jim Oberweis Recommends the Following Stocks: Dot Hill Systems and Kos Pharmaceuticals
CHICAGO--(BUSINESS WIRE)--Aug. 12, 2003--Is it time to take some profits? Jim Oberweis says 'no!', and instead offers a simple option strategy to limit risk and increase profit potential, along with a pair of his recent stock recommendations. Read about Dot Hill Systems Corporation (NASDAQ:HILL) and Kos Pharmaceuticals, Inc. (NASDAQ:KOSP). Click here for the full story exclusively on Zacks.com: http://featuredexpert2bw.zacks.com/ Here are the highlights from the Featured Expert column: BizVantage – The NOW newsletters, realtime with your content - for business, investment or technology. Selling calls, or more specifically writing "out-of-the-money" covered calls, on highly appreciated stocks may be an attractive alternative. This strategy can be used as a way to reduce overall portfolio volatility while remaining fully invested. Although the Oberweis team would never advocate timing the market, because it's impossible to get it consistently right, they would advise at least considering utilizing this very simple option strategy as a way to mitigate risk and increase income from some of your recent winners. Dot Hill Systems Corporation (NASDAQ:HILL) is a provider of data storage and networking solutions. The company designs, manufactures, markets and supports data storage products and systems for the open systems computing environments, including Windows NT, Solaris, Linux, HP-UX and AIX. Net revenue increased to $48.4 million for the second quarter of 2003, compared to $11.2 million for the second quarter of 2002, and $30.5 million for the first quarter of 2003. This represents a 332% increase year over year, and a 59% sequential increase. Kos Pharmaceuticals, Inc. (NASDAQ:KOSP) is a fully integrated specialty pharmaceutical company engaged in developing, commercializing, manufacturing and marketing proprietary prescription products for the treatment of chronic diseases. The company currently markets Niaspan(R) and Advicor(TM) for the treatment of cholesterol disorders. For the first quarter of 2003 ended March 31, revenue increased 101% to $68.3 million, up from $33.9 million for the first quarter 2002. Earnings for the quarter grew to $.35 vs. a loss in the March quarter a year ago. This quarterly earnings number included the effect of a change in product return estimates; excluding this one time item, the company earned $.08 a diluted share in the quarter. Get three more of Jim Oberweis' recommendations and make sure to read his complete commentary on covered call writing by clicking: http://featuredexpert3bw.zacks.com/ About Zacks Featured Experts To be a successful investor you need professional advice. Experts who know what they're talking about and can help you achieve your financial goals in good markets...and especially in bad ones will help you improve your portfolio. That is why Zacks Investment Research has assembled the best investment experts in the business to offer their powerful advisory newsletters to you on all the major investment topics: Stocks, Mutual Funds, Bonds, Options, Futures etc. Recommendations from Featured Experts Highlighted in FREE Investment Newsletter The best way to tap into the powerful advice from these experts is through our free weekly e-mail newsletter, "Profit from the Pros". Each week we highlight several Featured Experts in this free e-mail newsletter. Get your free subscription to "Profit from the Pros" at: http://www.freeprofit1bw.zacks.com About Zacks Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1981 to compile, analyze, and distribute investment research to both institutional and individual investors. The guiding principle behind our work is the belief that investment experts, such as brokerage analysts and investment newsletter writers, have superior knowledge about how to invest successfully. Our goal is to unlock their profitable insights for our customers. And there is no better way to enjoy this investment success, than with a FREE subscription to "Profit from the Pros" weekly e-mail newsletter. For your free newsletter, visit http://www.freeprofitbw.zacks.com Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates. Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
|
